Armistice Capital LLC trimmed its stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) by 6.1% in the fourth quarter, HoldingsChannel reports. The firm owned 1,536,000 shares of the company’s stock after selling 100,000 shares during the quarter. Armistice Capital LLC’s holdings in Alto Neuroscience were worth $27,341,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ANRO. Vivo Capital LLC bought a new position in Alto Neuroscience during the fourth quarter worth $18,433,000. Spruce Street Capital LP bought a new position in Alto Neuroscience during the fourth quarter worth $3,967,000. Northwestern Mutual Wealth Management Co. boosted its position in Alto Neuroscience by 14,567.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after purchasing an additional 211,222 shares during the period. Jane Street Group LLC bought a new position in Alto Neuroscience during the second quarter worth $240,000. Finally, Susquehanna International Group LLP boosted its position in Alto Neuroscience by 154.9% during the third quarter. Susquehanna International Group LLP now owns 155,676 shares of the company’s stock worth $626,000 after purchasing an additional 94,613 shares during the period.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on ANRO shares. Wedbush lifted their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Bank of America started coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price for the company. Wolfe Research started coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating for the company. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research report on Monday, March 16th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.
Alto Neuroscience Trading Up 4.2%
Shares of ANRO opened at $21.87 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The firm has a market cap of $767.49 million, a price-to-earnings ratio of -9.04 and a beta of 1.22. Alto Neuroscience, Inc. has a 52-week low of $2.15 and a 52-week high of $28.44. The business’s fifty day moving average is $22.68 and its 200-day moving average is $19.72.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Equities analysts anticipate that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.
Alto Neuroscience Profile
Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
Read More
- Five stocks we like better than Alto Neuroscience
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding ANRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alto Neuroscience, Inc. (NYSE:ANRO – Free Report).
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
